Jan 13, 2021
Montfort’s FDA-cleared neurological monitoring is used by healthcare facilities on four continents and is tracking post-Covid symptoms in Brazil.
By Abigail Klein Leichman, ISRAEL21c
People with chronic diseases are advised to stay home during the Covid-19 pandemic because they are at risk for complications should they become infected.
However, that makes it difficult to get essential medical monitoring for their conditions. And while Israel has emerged as a world leader in telemedicine, it’s easier to check heart rate and blood pressure remotely than to evaluate from a distance what is happening in the brain.
Now, patients with neurological disorders can be monitored in real time remotely, with an FDA-approved solution from Israeli startup Montfort.
DBusiness Magazine
Henry Ford Health System Using New Remote Neurological Monitor
Israel’s Montfort, a medical startup, has introduced its real-time, remote neurological monitor. The company’s board includes Peter LeWitt, professor of neurology at Detroit’s Wayne State University School of Medicine and director of Parkinson’s disease and movement disorders program at Detroit’s Henry Ford Hospital.
Montfort has introduced EncephaLog, an app-based solution to help physicians and patients better diagnose and treat neurological disorders. // Image courtesy of Montfort
Israel’s Montfort, a medical startup, has introduced its real-time, remote neurological monitor. The company’s board includes Peter LeWitt, professor of neurology at Detroit’s Wayne State University School of Medicine and director of Parkinson’s disease and movement disorders program at Detroit’s Henry Ford Hospital.
Share this article
Share this article
BINYAMINA, Israel, Dec. 16, 2020 /PRNewswire/ Montfort (Mon4t), an innovative medical startup introduces its real-time, remote neurological monitor.
Montfort s FDA-cleared solution leverages smartphone technology, big-data and AI to conduct digital neurological tests for patients with conditions such as Parkinson s disease, Huntington s disease, psychiatric disorders (like schizophrenia), as well as for patients with Post-COVID19 symptoms, some of which are similar to those observed in neurological conditions. About one billion people around the world suffer from neurological and psychiatric disorders. Diagnostics and treatment are based upon short and infrequent clinical visits thus limiting patients quality of care and increasing treatment costs - about 800 Billion USD in the US alone, says